| Next 10 |
Ad
HOOK Articles HOOKIPA Pharma Inc.
home / stock / hook / hook articles
Articles | HOOKIPA Pharma Inc. (NASDAQ:HOOK)
-
HOOKIPA Pharma Inc (NASDAQ:HOOK) shares are trading lower by 10.9% to $0.50 during Monday’s session after the company announced a 1-for-10 re...
-
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgr...
-
Company will present promising preliminary progression-free survival and overall survival data for patients with combined positive score (CPS) ??...
-
Monday, Roche Holdings AG (OTC:RHHBY) announced topline data from Phase 3 STARGLO study of Columvi (glofitamab) in combination ...
-
NEW YORK and VIENNA, Austria, March 06, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK, ‘HOOKIPA')), a company developing a ne...
-
Tuesday, Repare Therapeutics Inc (NASDAQ:RPTX) announced to regain global development and commercialization rights to camonsertib (RP-350...
-
HOOKIPA Pharma Inc (NASDAQ:HOOK) will focus its resources on prioritizing the clinical development of a randomized trial for its HB-200 progra...
-
On CNBC’s "Halftime Report Final Trades," Rob Sechan of NewEdge Wealth said Gilead Sciences, Inc. (NASDAQ: GILD) is an inexpensive...
-
NEW YORK and VIENNA, Austria, Jan. 16, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK, ‘HOOKIPA')), a company developing a new...
Stock Information
Get HOOK Alerts
News, Short Squeeze, Breakout and More Instantly...
HOOKIPA Pharma Inc. Company Name:
HOOK Stock Symbol:
NASDAQ Market:
0.0% G/L:
$1.17 Last:
18,942 Volume:
$1.17 Open:
$1.17 Close:
HOOKIPA Pharma Inc. Website:
Ad
-
NEW YORK and VIENNA, Austria, Jan. 07, 2025 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, “HOOKIPA”, the “Company”), a clinical-stage biopharmaceutical company developing next generation immunotherapeutics for the treatment of cancer and serious infectious dis...
-
Enrollment of 68 patients completed Phase 2 study for eseba-vec + pembrolizumab in HPV+ HNSCC four months ahead of schedule SITC 2024 late-breaking poster highlights Phase 2 eseba-vec data updates for increased number of patients reflecting ORR and durability in line with prior data ...
-
NEW YORK and VIENNA, Nov. 11, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, “HOOKIPA”, the “Company”), a clinical-stage biopharmaceutical company developing next generation immunotherapeutics for the treatment of cancer and serious infectious disease, tod...
Important Investor News Alert (OTC: AVAI)
-
LAS VEGAS, NV / ACCESS Newswire / March 10, 2025 / Avant Technologies Inc. (OTCQB:AVAI) ("Avant" or the "Company"), and its partner, Ainnova Tech, Inc., (Ainnova), a leading healthcare technology company focused on revolutionizing early disease detection using artificial intelligence (AI), tod...